To evaluate the benefits in functional status and labor productivity of tofacitinib in patients with inadequate response to a non-biological DMARD vs anti-TNF in Colombia. The response to treatment was assessed by the change from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) from baseline and works lost productivity: absenteeism and presenteeism (productivity reduction ≥50%) due patient’s functional status, as reported by Chaparro del Moral R. 2012 and Hazes JM. 2010 who measured absenteeism according to functional status regardless of treatment received. Comparison between anti-TNF and tofacitinib (5mg BID) was done directly to adalimumab (heat-to-heat study) and indirectly (Bucher´s indirect comparisons adjusted method) vs other anti-TNF available in Colombia (certolizumab, etanercept, golimumab and infliximab) using methotrexate as reference therapy. A discrete event model that simulates six cohorts of 1,000 patients (each per treatment option) was developed; productivity hours lost was projected according to HAQ level (<0.5; 0.5-0.87; >0.87), during 52 weeks horizon. Variations in HAQ levels (basal and weekly mean chance), absenteeism and presenteeism hours were probabilistically generated assuming a normal distribution. The results obtained with the anti-TNF’s are grouped and weighted given their market share as reported in the SISMED by the Health Ministry. Improvement in HAQ-DI score at 3, 6, 9 and 12 months from baseline with tofacitinib and anti -TNF were 61.9, 48.7, 65.2 and 53.2%; and, 49.5, 42.7, 57.1 and 47.1%, respectively (t-test at 52 weeks, p<0.001). As result of these reductions, the hours of absenteeism/presenteeism losses along the 52-week horizon were obtained, at last observation week: 2.72/2.67 and 4.04/7.23 hours with tofacitinib and anti-TNF respectively. The superior reduction in HAQ-DI scale at 52 weeks obtained with Tofacitinib in patients with inadequate response to a non-biological DMARD results in a greater reduction in work lost productivity, presenteeism and absenteeism, compared to anti-TNF available in Colombia.